Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-21 02:28 | 2025-05-19 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $11.84 | 2,600 | $30,791 | 95,557 |
| 2025-05-21 02:28 | 2025-05-19 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $11.84 | 3,808 | $45,097 | 293,367 |
| 2025-05-21 02:27 | 2025-05-19 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $11.84 | 2,776 | $32,876 | 106,611 |
| 2025-05-21 04:44 | 2025-05-20 | MNKD | MANNKIND CORP | Thomson David | Officer | SELL | $4.41 | 2,345 | $10,341 | 879,546 |
| 2025-05-20 23:05 | 2025-05-16 | RCKT | ROCKET PHARMACEUTICALS, INC. | Militello John | Officer | SELL | $6.53 | 655 | $4,276 | 64,384 |
| 2025-05-20 23:05 | 2025-05-16 | RCKT | ROCKET PHARMACEUTICALS, INC. | Patel Kinnari | Officer | SELL | $6.53 | 1,409 | $9,198 | 442,694 |
| 2025-05-20 23:05 | 2025-05-16 | RCKT | ROCKET PHARMACEUTICALS, INC. | Schwartz Jonathan David | Officer | SELL | $6.53 | 1,582 | $10,327 | 236,056 |
| 2025-05-20 23:05 | 2025-05-16 | RCKT | ROCKET PHARMACEUTICALS, INC. | Shah Gaurav | Director, Officer | SELL | $6.53 | 3,621 | $23,638 | 789,059 |
| 2025-05-20 23:05 | 2025-05-16 | RCKT | ROCKET PHARMACEUTICALS, INC. | Wilson Martin | Officer | SELL | $6.53 | 946 | $6,175 | 149,750 |
| 2025-05-20 23:34 | 2025-05-16 | HCWB | HCW Biologics Inc. | GARRETT SCOTT T | Director | BUY | $7.45 | 13,423 | $100,001 | 25,505 |
| 2025-05-20 23:00 | 2025-05-19 | ZOMDF | Zomedica Corp. | POWERS JOHNNY D | Director | BUY | $0.05 | 500,000 | $23,000 | 3,425,000 |
| 2025-05-20 23:01 | 2025-05-16 | GYRE | GYRE THERAPEUTICS, INC. | Ma Songjiang | Director, Officer | SELL | $11.21 | 4,000 | $44,840 | 2,814,824 |
| 2025-05-21 02:35 | 2025-05-16 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $74.17 | 32,262 | $2,393,014 | 5,487 |
| 2025-05-21 02:13 | 2025-05-16 | CORT | CORCEPT THERAPEUTICS INC | MAHONEY DAVID L | Director | OPT+S | $74.23 | 27,352 | $2,030,454 | 0 |
| 2025-05-20 23:32 | 2025-05-15 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $295.10 | 11,000 | $3,246,150 | 36,781 |
| 2025-05-20 23:28 | 2025-05-20 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $31.98 | 2,000 | $63,960 | 140,255 |
| 2025-05-21 01:56 | 2025-05-16 | XOMA | XOMA Royalty Corp | BVF PARTNERS L P/IL | 10% owner | SELL | $27.10 | 392,723 | $10,642,793 | 1,267,545 |
| 2025-05-21 00:58 | 2025-05-20 | BMRN | BIOMARIN PHARMACEUTICAL INC | Burkhart Erin | Officer | SELL | $59.31 | 1,786 | $105,928 | 14,173 |
| 2025-05-19 23:30 | 2025-05-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $9.56 | 8,500 | $81,262 | 452,142 |
| 2025-05-20 04:25 | 2025-05-13 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | GARNETT KEITHLY | Officer | BUY | $7.01 | 90 | $631 | 330,000 |
| 2025-05-20 04:24 | 2025-05-12 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | CHEN THOMAS C | Director, Officer, 10% owner | BUY | $7.00 | 400 | $2,800 | 546,200 |
| 2025-05-20 00:49 | 2025-05-15 | CNTA | Centessa Pharmaceuticals plc | GOYAL ARJUN | Director | BUY | $12.68 | 462,585 | $5,865,254 | 462,585 |
| 2025-05-20 00:54 | 2025-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | Merendino Lauren | Officer | OPT+S | $6.26 | 3,927 | $24,575 | 35,161 |
| 2025-05-20 00:44 | 2025-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | Director, Officer | OPT+S | $6.26 | 13,964 | $87,385 | 145,737 |
| 2025-05-19 23:54 | 2025-05-16 | JBIO | Jade Biosciences, Inc. | Frohlich Tom | Director, Officer | BUY | $7.40 | 6,000 | $44,400 | 6,000 |
| 2025-05-20 02:06 | 2025-05-15 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Officer | OPT+S | $39.30 | 10,000 | $392,978 | 95,034 |
| 2025-05-20 00:48 | 2025-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | Officer | OPT+S | $6.26 | 4,552 | $28,486 | 47,136 |
| 2025-05-19 23:16 | 2025-05-16 | AMRX | Amneal Pharmaceuticals Inc. | Shah Nikita | Officer | SELL | $7.58 | 49,140 | $372,481 | 388,929 |
| 2025-05-19 23:44 | 2025-05-15 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | Officer | OPT+S | $0.00 | 100,000 | $0 | 44,000 |
| 2025-05-20 00:45 | 2025-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | Officer | OPT+S | $6.26 | 4,282 | $26,796 | 265,231 |
| 2025-05-19 23:05 | 2025-05-16 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | Officer | OPT+S | $7.28 | 63 | $459 | 5,044 |
| 2025-05-19 23:05 | 2025-05-16 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Director, Officer | OPT+S | $7.28 | 220 | $1,602 | 10,102 |
| 2025-05-19 23:05 | 2025-05-16 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | Officer | OPT+S | $7.28 | 77 | $561 | 4,383 |
| 2025-05-20 04:27 | 2025-03-26 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | Delshad Jim | Director | BUY | $7.31 | 5,100 | $37,258 | 55,310 |
| 2025-05-20 00:33 | 2025-05-15 | OKUR | OnKure Therapeutics, Inc. | Cormorant Asset Management, LP | SELL | $1.85 | 1,813,439 | $3,363,023 | 0 | |
| 2025-05-20 00:07 | 2025-05-15 | VRTX | VERTEX PHARMACEUTICALS INC / MA | ALTSHULER DAVID | Officer | SELL | $424.69 | 52 | $22,084 | 23,281 |
| 2025-05-20 01:35 | 2025-05-15 | ZYME | Zymeworks Inc. | EcoR1 Capital, LLC | Director, 10% owner | BUY | $11.47 | 55,421 | $635,585 | 17,883,908 |
| 2025-05-20 02:02 | 2025-05-11 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | Heshmatpour Amir F | Director, Officer | BUY | $10.65 | 10,000 | $106,515 | 1,760,000 |
| 2025-05-19 23:05 | 2025-05-15 | MCRB | Seres Therapeutics, Inc. | DesRosier Thomas | Officer | OPT+S | $7.28 | 79 | $575 | 7,287 |
| 2025-05-20 01:30 | 2025-05-19 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | Officer | SELL | $5.96 | 1,559 | $9,292 | 107,948 |
| 2025-05-20 01:30 | 2025-05-19 | KURA | Kura Oncology, Inc. | FORD KATHLEEN | Officer | SELL | $6.28 | 1,558 | $9,777 | 21,367 |
| 2025-05-19 23:04 | 2025-05-19 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | Officer | BUY | $0.00 | 3,000 | $0 | 93,746 |
| 2025-05-19 23:03 | 2025-05-16 | SNDX | Syndax Pharmaceuticals Inc | Botwood Nicholas A.J. | Officer | BUY | $9.00 | 11,765 | $105,826 | 35,165 |
| 2025-05-19 23:02 | 2025-05-19 | SNDX | Syndax Pharmaceuticals Inc | Huber Martin H. Jr. | Director | BUY | $8.99 | 5,000 | $44,950 | 79,000 |
| 2025-05-19 23:43 | 2025-05-15 | OKUR | OnKure Therapeutics, Inc. | ACORN BIOVENTURES, L.P. | 10% owner | BUY | $1.85 | 1,400,000 | $2,590,000 | 1,129,730 |
| 2025-05-19 23:14 | 2025-05-15 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | BUY | $13.62 | 2,520 | $34,317 | 17,494 |
| 2025-05-20 00:13 | 2025-05-16 | VNDA | Vanda Pharmaceuticals Inc. | Polymeropoulos Mihael Hristos | Director, Officer | BUY | $4.22 | 20,000 | $84,472 | 2,315,731 |
| 2025-05-19 23:01 | 2025-05-19 | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Director | BUY | $9.11 | 10,000 | $91,120 | 100,000 |
| 2025-05-20 00:02 | 2025-05-15 | ARDX | Ardelyx Inc. | MOTT DAVID M | Director | BUY | $3.29 | 100,000 | $329,120 | 2,496,871 |
| 2025-05-19 23:17 | 2025-05-15 | ALNY | Alnylam Pharmaceuticals Inc. | BONNEY MICHAEL W | Director | OPT+S | $277.71 | 11,250 | $3,124,217 | 16,804 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.